Most enrollees reported satisfaction with their health plans, although some concerns exist.
Diana DeGette
The Public Record
Diana Louise DeGette is a U.S. Representative for Colorado's 1st congressional district, having served since January 3, 1997. A member of the Democratic Party, she has been a prominent advocate for health care reform and women's rights throughout her tenure in Congress. DeGette has played a significant role in various legislative efforts, particularly in expanding access to health care services. Her work has garnered support from organizations such as the National Association of Community Health Centers.
There are thousands of families in the United States who are benefiting in the way my family has, and I am going to fight until the end to make sure that they can keep these benefits.
Nobody wants to see waste, fraud, and abuse. We are opposed on a bipartisan basis to waste, fraud, and abuse.
I just want to clarify a couple of things that we have been talking about this morning.
If this CSR fund is struck down by the court then 6.4 million people will lose their subsidies.
The Constitution clearly states that the power of the purse lies not with the Executive, but with the Congress.
If they think what they are doing is legal, then come before this committee and explain it.
There are clear problems with the law if the Administration must violate the Constitution to keep the law afloat.
For the alleged 'most transparent Administration in history,' this Administration is trying its utmost to avoid Congressional scrutiny.
I really don't question the motives of the majority here. I think it is in the congressional prerogative to file a lawsuit if Congress believes that the Administration has overstepped its constitutional bounds.
This report last month about the superbug has been quite concerning to all of us.
The goal of the biopharmaceutical accelerator will be in collaboration with our partners at NIAID.
We have been worried for quite some time here in Congress and at the agencies about the risk of resistant antibiotics.
I wish you would, thanks, because maybe that can help illuminate--yes, Dr. Hatchett?
We need a full panoply of investment in the research, the basic science, the drug discovery and drug development that lasts.
The bacterium's resistance to colistin is particularly concerning because in this country physicians use colistin as the treatment of last resort.
I worry that the bills that are under discussion today will actually increase costs and also harm access to insurance.
myself and Congressman Bilirakis have introduced a bill that talks about lowering drug costs through competition.
Today's hearing is an important opportunity to discuss ways to strengthen two critically important government programs that serve over 100 million Americans: Medicare and Medicaid.
Frequently here in Congress we try to get our government agencies to act like private businesses and it doesn't always translate a hundred percent.





